Estimating All-Cause Deaths Averted in the First Two Years of the COVID-19 Vaccination Campaign in Italy
Open Access
Abstract
Comparing deaths averted by vaccination campaigns is a crucial public health endeavour. Excess all-cause deaths better reflect the impact of the pandemic than COVID-19 deaths. We used a seasonal autoregressive integrated moving average with exogenous factors model to regress daily all-cause deaths on annual trend, seasonality, and environmental temperature in three Italian regions (Lombardy, Marche and Sicily) from 2015 to 2019. The model was used to forecast excess deaths during the vaccinal period (December 2020–October 2022). We used the prevented fraction to estimate excess deaths observed during the vaccinal campaigns, those which would have occurred without vaccination, and those averted by the campaigns. At the end of the vaccinal period, the Lombardy region proceeded with a more intensive COVID-19 vaccination campaign than other regions (on average, 1.82 doses per resident, versus 1.67 and 1.56 in Marche and Sicily, respectively). A higher prevented fraction of all-cause deaths was consistently found in Lombardy (65% avoided deaths, as opposed to 60% and 58% in Marche and Sicily). Nevertheless, because of a lower excess mortality rate found in Lombardy compared to Marche and Sicily (12, 24 and 23 per 10,000 person-years, respectively), a lower rate of averted deaths was observed (22 avoided deaths per 10,000 person-years, versus 36 and 32 in Marche and Sicily). In Lombardy, early and full implementation of adult COVID-19 vaccination was associated with the largest reduction in all-cause deaths compared to Marche and Sicily.Keywords
Funding Information
- PoliS-Lombardia (H45H20000400002)
This publication has 73 references indexed in Scilit:
- Estimated Effectiveness of a Primary Cycle of Protein Recombinant Vaccine NVX-CoV2373 Against COVID-19JAMA Network Open, 2023
- Efficacy of physiological seawater nasal irrigation for the treatment of children with SARS-CoV-2 Omicron BA.2 variant infection: a randomized controlled trialWorld Journal of Pediatrics, 2023
- Effectiveness of mRNA and viral‐vector vaccines in epidemic period led by different SARS‐CoV‐2 variants: A systematic review and meta‐analysisJournal of Medical Virology, 2023
- Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe OutcomesJAMA Network Open, 2022
- COVID-19 vaccinations: An overview of the Italian national health system's online communication from a citizen perspectiveHealth Policy, 2022
- Comparative effectiveness and durability of COVID‐19 vaccination against death and severe disease in an ongoing nationwide mass vaccination campaignJournal of Medical Virology, 2022
- Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta VariantsJAMA, 2022
- Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary—the HUN-VE studyClinical Microbiology and Infection, 2021
- The BNT162b2 vaccine effectiveness against new COVID-19 cases and complications of breakthrough cases: A nation-wide retrospective longitudinal multiple cohort analysis using individualised dataEBioMedicine, 2021
- Nonpharmaceutical Interventions Implemented by US Cities During the 1918-1919 Influenza PandemicJAMA, 2007